Veracyte's Thyroid Cancer MDx Gets New York State OK | GenomeWeb

NEW YORK (GenomeWeb News) – Veracyte and Genyzme today announced that the New York State Department of Health has cleared the way for Veracyte's molecular diagnostic test for inconclusive thyroid nodule results to be offered to patients in the state.

Memorial Sloan-Kettering Cancer Center will become one of the first institutions in the state to offer the test, which helps resolve inconclusive thyroid nodule results following traditional evaluation of fine needle aspiration (FNA) samples, the companies added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.